<DOC>
	<DOC>NCT00120692</DOC>
	<brief_summary>The purpose of this study is to validate a Patient Satisfaction Questionnaire for Anemia Treatment (PSQ-AT) in female breast cancer patients treated with darbepoetin alfa or recombinant human erythropoietin (rHuEPO) for anemia due to chemotherapy.</brief_summary>
	<brief_title>Treatment for Patients Suffering From Anemia Due to Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Female subjects receiving multicycle chemotherapy Anemia due to chemotherapy (hgb less than or equal to 11.0 g/dL) Expected to receive greater than or equal to 8 additional weeks of chemotherapy as part of their planned treatment Karnofsky Performance Scale (KPS) greater than or equal to 50% Adequate renal function Adequate liver function Iron deficiency Unstable cardiac disease Known positive test for human immunodeficiency virus (HIV) infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>darbepoetin alfa</keyword>
	<keyword>Amgen</keyword>
</DOC>